Home
overview

SMi’s 6th Conference on ‘Therapeutic Antibodies’ will provide a forum for leading industry experts from major pharmaceutical companies to discuss and evaluate the latest challenges and problems facing the therapeutic antibodies market.

It is predicted that therapeutic antibodies will form one of the fastest growing segments of the pharmaceutical market, and is expected to be worth more than $86 billion dollars by the year 2025. The success of current marketed products has led to an explosion in antibody development, with hundreds of programmes currently in the pipeline.

This conference will discuss the latest developments and outline the most recent trends and innovations in the therapeutic antibodies market. Particular focus will be given to the latest regulatory standards and intellectual property, which affect developments in this market.

SMi’s Therapeutic Antibodies conference is a must attend event and will provide an excellent opportunity to network, enhance your company’s profile and keep you up-to-date on the latest issues in the market.

An unique opportunity to learn from leading industry experts, including:

  • Dr Rene Hoet, Director, Research & Technology, Dyax
  • Dr John de Kruif, Director, Antibody Research & Development, Crucell
  • Dr Dave Estell, Vice President, Technology, Genencor
  • Dr Robert Friesen, Director, Preclinical Development, MorphoSys
  • Dr Diane Wilcock, Vice President, Intellectual Property, Cambridge Antibody Technology
  • Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics
  • Dr Hans de Haard, Scientific Director, Ablynx
  • Elisabeth Wassner, Clinical Scientist, F. Hoffmann-La Roche
  • Dr Frederic Fellouse, Senior Research Scientist, Genentech

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Søren  Bregenholt

Dr Søren Bregenholt, Director, Project Management, Symphogen

9:10 OVERVIEW OF THE THERAPEUTIC ANTIBODIES MARKET

Dr Mark Belsey

Dr Mark Belsey, Biotechnology Analyst, Datamonitor

  • Market overview
  • Exploring the European therapeutic antibodies market
  • Improving the efficacy of mab therapeutics likely to benefit growth
  • Technology trends
  • The road ahead
  • 9:50 ASSESSING AND GENERATING ANTIBODY IP

  • IP landscape for antibody phage display
  • Comparison of USPTO and EPO approaches to antibody claims
  • Strategies for protecting antibodies
  • Approaches for assessing third party antibody patents
  • Dr Diane Wilcock

    Dr Diane Wilcock, Vice President, Intellectual Property, Cambridge Antibody Technology

    10:30 Morning Coffee

    11:00 PRECLINICAL DEVELOPMENT

    Dr Robert Friesen

    Dr Robert Friesen, Director, Preclinical Development, Morphosys A G

  • HuCAL ® Human Combatorial Antibody Library
  • Therapeutic antibodies in development
  • MOR antibody development
  • Collaborative development programmes

  • 11:40 SYNTHETIC THERAPEUTIC ANTIBODIES

  • Application of structure- based design to antibody development
  • High affinity antibodies dervied from synthetic repertoires
  • Structural and functional analysis of antigen recognition
  • Highly optimised synthetic libraries with limited amino acid diverisities
  • Implications for antibody engineering and therapeutic antibodies
  • Dr Frederic Fellouse

    Dr Frederic Fellouse, Research Scientist, Genetech Inc

    12:20 Networking Lunch

    13:50 ANTIBODY PHAGE DISPLAY

    Dr Rene Hoet

    Dr Rene Hoet, Senior Director, Discovery Research , Dyax

  • Construction and use of Dyax novel phage and phagemid human antibody libraries
  • Novel antibody diversity combining careful synthetic design with natural human human donor diversity
  • Automated controlled phage display selcetion methods on purified protein targets, peptides and cells
  • High throughput screening methods to identify antibody leads
  • Case study: Tie-1 targeted inhibitor of tumour growth
  • 14:30 ANTIBODY ENGINEERING

  • Can antibody effector function be reliably measured in whole blood by flow cytometry ?
  • Can models be established that predicts clinical observations ?
  • Can this data be used to delineate mechanism of action ?
  • Can such assays demonstrate on-target effects ?
  • Dr John Ferbas

    Dr John Ferbas, Principal Scientist, Group Leader, Flow Cytometry & Laser Scanning Cytometry Laboratories, Amgen

    15:10 Afternoon Tea

    15:40 PRACTICAL MEASURES FOR REDUCING IMMUNOGENICITY

    Dr Dave Estell

    Dr Dave Estell, Vice President, Technology Research, Genencor International Inc

  • Factors that influence immunogenicity of therapeutic proteins
  • Identification of T cell epitopes
  • Determining relative immunogenicity of proteins
  • Modification of T cell epitopes to reduce immunogencity
  • 16:20 IMMUNOGENICITY AND REGULATORY STANDARDS

    Dr Leon Hooftman

    Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics

  • Clinical development aspects
  • Identification and optimisation of immunogenic epitopes
  • Regulatory authorities - a long process to the final stage
  • The movement of antibody products from CBER to CDER
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Hans de Haard

    Dr Hans de Haard, Scientific Director, Ablynx

    9:10 DEVELOPMENT OF THERAPEUTIC ANTIBODIES TO GENOMIC DERIVED TARGETS

    Dr Vivian Albert

    Dr Vivian Albert, Vice President, Development Sciences & Research, Human Genome Sciences

    9:50 NEW INNOVATIONS IN THE THERAPEUTIC ANTIBODIES MARKET

    Dr Patrick Dufner

    Dr Patrick Dufner, Research Scientist, Cambridge Antibody Technology

  • CAT-354 for treatment of severe asthma, an affinity-matured human anti-IL-13 antibody
  • Identification of mutation hot-spots and their synergistic contribution to antibody potency improvements
  • Exploring antibody-antigen interaction
  • optimisation of biophysical characteristics like stability or solubility
  • Application to other therapeutic proteins
  • 10:30 Morning Coffee

    11:00 RITUXIMAB - CHANGING THE LANDSCAPE OF NHL/CLL TREATMENT

  • Brief review of NHL/CLL disease area and potential targets for antibody treatment
  • Treatment algorithms over the last 25 years in NHL/CLL
  • Structure and mode of action of Rituximab
  • Key data generated and published in the last few years
  • Impact of Rituximab on treatment guidelines and habits of NHL/CLL
  • Lessons we learnt so far to further improve antibody treatment in NHL/CLL
  • Elisabeth  Wassner

    Elisabeth Wassner, Clinical Scientist, F. Hoffman- La Roche

    11:40 PATIENT SPECIFIC ANTIBODY THEREAPY FOR NON-HODGKINS LYMPHOMA

    Dr Dana Ault-Riche

    Dr Dana Ault-Riche, Chief Executive Officer, Pointilliste

  • Patient specific drug development
  • Rapid identification of recombinant antibodies using microarray displays
  • Rapid formulation of recombinant antibodies into therapeutic molecules
  • Functional cell-based screening of antibody libraries using microarray displays
  • 12:20 Networking Lunch

    13:50 INFECTIOUS DISEASES

    Dr John de Kruif

    Dr John de Kruif, Director, Antibody Reasearch and Development, Crucell

  • Isolation of antibody specificities
  • Characterisation of antigens - epitopes and affinities
  • In vitro functional performance of teh antibodies
  • In vivo studies in small animals
  • 14:30 HOW CAMBRIDGE ANTIBODY TECHNOLOGY DELIVERS LEADS

    Dr Gerald Beste

    Dr Gerald Beste, Team Leader, Lead Discovery, Cambridge Antibody Technology

  • Overview of selection therapies
  • Screening for function
  • IgG conversion
  • 15:10 Afternoon Tea

    15:40 USING NANOBODIES AS NEW THERAPEUTIC ENTITIES

    Dr Hans de Haard

    Dr Hans de Haard, Scientific Director, Ablynx

  • The unique properties of Nanobodies and their potential as breakthrough therapeutics
  • Nanobodies against TNFa for the prevention of rheumatoid arthritis and inflammatory bowel disease
  • Anti Von Willebrand factor Nanobodies for prevention of arterial thrombosis
  • Nanobodies against CEA and EGFR for the treatment of cancer

  • 16:20 DEVELOPMENT OF RECOMBINANT HUMAN POLYCLONAL ANTIBODY THERAPEUTICS

    Dr Søren  Bregenholt

    Dr Søren Bregenholt, Director, Project Management, Symphogen

  • Innovative technology for cloning cognate human antibodies
  • Expression of recombinant human polyclonal antibodies
  • Regulatory strategy for obtaining approval of recombinant polyclonal antibody pharmaceuticals
  • Development of Sym001; anti-RhD polyclonal antibodies for treatment of ITP and HDN
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Commercialising Antibodies
    Workshop

    Commercialising Antibodies

    Park Street Training and Meeting Centre, at etc. venues
    1st February 2006
    London, United Kingdom

    Cancer and Therapeutic Antibodies
    Workshop

    Cancer and Therapeutic Antibodies

    Park Street Training and Meeting Centre, at etc. venues
    1st February 2006
    London, United Kingdom

    Mayfair Conference Centre

    17 Connaught Mews
    London W2 2EL
    United Kingdom

    Mayfair Conference Centre

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.